The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients With Early-Stage Breast Cancer
Value in Health - United Kingdom
doi 10.1016/j.jval.2015.01.012
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2015
Authors
Publisher
Elsevier BV